Actively Recruiting
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
Led by Massachusetts General Hospital · Updated on 2026-02-27
72
Participants Needed
1
Research Sites
362 weeks
Total Duration
On this page
Sponsors
M
Massachusetts General Hospital
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this study is to investigate the efficacy of \[68Ga\]CBP8 to detect collagen deposition in radiation induced tissue injury.
CONDITIONS
Official Title
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults older than 18 years
- For lung cancer: locally advanced stage I-III NSCLC patients not eligible for surgery or stage IIIa NSCLC eligible for multimodality therapy
- For pancreatic cancer: diagnosis of pancreatic ductal adenocarcinoma confirmed by histology or cytology
- Pancreatic cancer patients must have tumor confirmed by baseline abdominal CT within 1 month before study
- Ability to give written informed consent
- No tobacco use within 6 months
- Life expectancy greater than 3 months for pancreatic cancer subjects
- Scheduled to undergo neoadjuvant chemoradiotherapy and surgical pancreas resection as standard care
- Availability of core samples for initial diagnosis at Massachusetts General Hospital pathology department
- No prior or concurrent malignancy interfering with safety or efficacy assessment
You will not qualify if you...
- Presence of electrical implants such as cardiac pacemaker or perfusion pump
- Presence of ferromagnetic implants like aneurysm clips, surgical clips, prostheses, artificial hearts with steel parts, metal fragments, shrapnel, or metallic tattoos especially near the eye
- Pregnant or breastfeeding females (negative pregnancy test required for those of child-bearing potential)
- Claustrophobia preventing MRI/PET scans
- Research-related radiation exposure exceeding 50 mSv in the last 12 months
- Inability to lie comfortably inside the MR-PET scanner
- Body weight over 300 lbs (lung cancer) or BMI over 33 (pancreatic cancer)
- Known history of pulmonary disease excluding lung cancer or smoking-related lung disease
- Pneumonia or other acute respiratory illness within 6 weeks before study entry
- History of radiotherapy to upper abdomen (pancreatic cancer)
- History of reaction to MRI contrast agent (Gadoterate meglumine)
- Acute pancreatitis diagnosed clinically or by imaging within 6 weeks prior to study
- Uncontrolled intercurrent illness or psychiatric/social situations limiting compliance
- Estimated glomerular filtration rate (eGFR) less than 30 mL/min/1.73 m2 within past 90 days (pancreatic cancer)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Actively Recruiting
Research Team
M
Michael Lanuti, MD
CONTACT
S
Shadi Esfahani, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here